Divis Laboratories Ltd 2025 AR2
The report highlights Divi's Laboratories Limited's performance for the fiscal year 2024-2025, emphasizing its leadership in Active Pharmaceutical Ingredients (APIs). Key achievements include the commencement of commercial operations at the Kakinada Unit 3 greenfield project and a successful US FDA inspection at Unit 2. Financially, the company achieved a total income of INR 9,550 crores and a profit after tax of INR 2,209 crores. On the sustainability front, Divi's conserved approximately 34,870 GJ of energy, 92,130 KL of water, and reduced greenhouse gas emissions by around 6,350 t CO2e.
Company: Divis Laboratories Ltd
Sector: Health Care
Country: India
Year: 2025
Type: AR2
Pages: 140
Divis Laboratories Ltd
Annual Report
The report highlights Divi's Laboratories Limited's performance for the fiscal year 2024-2025, emphasizing its leadership in Active Pharmaceutical Ingredients (APIs). Key achievements include the commencement of commercial operations at the Kakinada Unit 3 greenfield project and a successful US FDA inspection at Unit 2. Financially, the company achieved a total income of INR 9,550 crores and a profit after tax of INR 2,209 crores. On the sustainability front, Divi's conserved approximately 34,870 GJ of energy, 92,130 KL of water, and reduced greenhouse gas emissions by around 6,350 t CO2e.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees